×
CLPT fell -21.88% intraday on September 29, 2026, sliding from a $15.31 prior-session close to $11.96 during regular market hours. The sharp decline follows ongoing pressure tied to a recently lowered FY2026 revenue outlook ($48M–$52M, down from $52M–$56M) and widening losses.
Gene therapy approvals are the defining catalyst: Multiple biopharma partners are advancing toward Biologics License Application (BLA) submissions, potentially triggering a new commercial phase for ClearPoint's drug-delivery tools. Four-pillar growth strategy: Management expects double-digit growth across biologics and drug delivery, neurosurgery navigation, laser therapy, and neurocritical care in 2026.
ARAY is down roughly -15.28% in regular trading, near $0.254 versus Monday's $0.2998 close. The move is a pullback and profit-taking after Monday's +39.5% surge (intraday peak +77.6%) on the Samsung NeuroLogica volumetric imaging collaboration for CyberKnife.
CLPT fell -21.62% intraday to about $12.00, down from its prior-session close of $15.31. The -$3.31 per-share decline unfolded during regular market hours (as of roughly 9:41 a.m. ET).
Inspire Medical Systems (INSP) shares climbed roughly 11% over the trailing 30 days, moving from about $61.80 to near $68.66. The advance extends a broader recovery, with the stock up more than 50% over the trailing three months after a difficult first half of the year.
AEMD surged +374.13% to close at $6.78, up from $1.43 the prior session, after announcing a definitive all-stock merger with privately held biotech North Immunology. The move began in premarket trading, where shares spiked roughly +400% and opened at $8.54 before settling lower into the close.
10x Genomics (TXG) shares rose roughly 31% over the trailing 30 days, climbing from about $55.63 to a latest close of $72.68, and touched a new 52-week high. The rally built on a much larger multi-month surge, with the stock up more than 100% over the past quarter and over 300% year to date.
TNON gained +50.75% during Friday's regular session, trading around $7.99 versus the prior close of $5.30. The move extends a multi-day surge sparked by the Sept. 9 announcement that it repaid $5.16M in senior convertible notes early, ahead of their Sept. 11 maturity, removing discounted-conversion dilution risk.
Stryker (SYK) shares fell about 22% over the last 30 days, sliding from roughly $347 to near $270 and trading at or near 52-week lows. The sell-off accelerated in early September after management warned that manufacturing and supply problems in its peripheral vascular business would persist into the fourth quarter.
AXGN fell -9.92% to $42.58 during regular trading, from a prior-session close of $47.27. Primary catalyst: the company priced a 4.91M-share underwritten public offering at $42.50, a >10% discount that dilutes existing shareholders.
Tenon Medical (TNON) shares have fallen roughly 60% over the past 30 days, closing at $2.44 on September 9, 2026, down from $6.14 in early August. The move reflects a 1-for-35 reverse stock split, continued share dilution, and a second-quarter earnings miss, only partly offset by the full repayment of convertible notes.
The selected price objective is $200 per share , roughly 35% above Insulet's recent trading range near $148. The strongest bullish case rests on an underpenetrated Type 2 diabetes market, double-digit international growth, and a recurring "razor-and-blade" consumables model.
The central question is whether NeuroPace (NPCE) can reach a $20 stock price target , a level aligned with the Wall Street consensus and roughly 35% above recent trading levels. Bullish support comes from strong revenue growth, a growing prescriber base, FDA-approved AI tools, and a potential expansion into idiopathic generalized epilepsy (IGE).
AMIX surged +46.74% to $7.88, up from the prior session's close of $5.37, with the gain extending through premarket and regular trading hours. The move followed the company's announcement of a $4.9 million warrant inducement agreement, priced at a premium under Nasdaq rules.
The most widely cited public price objective for Autonomix Medical, Inc. (NASDAQ: AMIX) is the $42 analyst price target issued by Maxim Group, a level that would require a roughly seven-fold move from recent prices. AMIX is a development-stage medical device company with no reported revenue, a shrinking cash balance, and a history of dilutive capital raises.
VREX closed up +0.11% (+$0.02) at $18.51 in Friday's regular session, the latest completed session before Monday's open. The gain reflects consolidation, with shares pinned just below the $18.90 per-share all-cash Teledyne Technologies acquisition offer (~$1.1 billion, announced Aug. 10).
Delcath Systems (DCTH) climbed roughly 40% over the past 30 days, rising from about $12.22 to $17.14. The rally was driven by stronger-than-expected second-quarter 2026 results, reported before the open on August 6, 2026.
The selected price target is $11 per share , the highest current analyst target and a level just above the stock's 52-week high of $10.05. Butterfly Network has delivered record quarterly revenue, raised its full-year guidance, and holds a "Strong Buy" consensus, the strongest bullish factors supporting further upside.
Selected price target: $15 per share, roughly 25% above recent trading levels near $12 and about 17% above the 52-week high of $12.85. Bullish factors: A recovery in the animal-safety business, improving food-safety margins, portfolio simplification through divestitures, and a series of analyst target increases.
Profusa shares are up +233.11% to $15.09 in Tuesday regular trading as of 10:29 a.m. ET, versus Monday's close of $4.53. The move extends premarket and overnight gains after the company's 1-for-4 reverse stock split became effective, reducing shares outstanding from about 2.42 million to roughly 605,726.
Previous
26 of 31
Next